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 Abstract 
 
Purpose: The aim of this study was to examine long-term outcomes in patients who 
received salvage radiotherapy (SRT) for biochemical recurrence (BRec) of prostate 
cancer after radical prostatectomy (RP). 
Materials and Methods: One hundred twenty patients with prostate cancer who 
underwent SRT for BRec after RP without evidence of clinical disease were identified 
in our institution from 2002 to 2014. Prescription doses to prostate beds were 64.8 Gy 
with a fractional dose of 1.8 Gy in 96.7% of the patients. In three-dimensional 
conformal radiation therapy (3D-CRT), the seminal vesicle bed (SVB) was not included 
in the radiation fields. The prognostic factors for BRec–free survival (BRFS) and 
incidence of acute and late toxicities were investigated.  
Results: Median follow-up duration after SRT was 64.9 months. The 5-year rates of 
BRFS, overall survival (OS), cause-specific survival (CSS), and clinical recurrence-free 
survival (CRFS) were 39.2%, 97.0%, 98.3%, and 91.9%, respectively. Only two 
patients experienced late grade 3 toxicity of hematuria. Multivariate analysis revealed 
that BRFS was significantly favorable in patients with prostate-specific antigen (PSA) 
values < 0.5 ng/mL at the initiation of SRT and pathological Gleason score not 
including Gleason grade 5. In patients treated with 3D-CRT, a positive surgical margin 
at the base of the prostate influenced BRFS unfavorably in comparison to positive 
surgical margins at other sites. 
 Conclusion: SRT for patients with BRec after RP was performed very safely in our 
institution. However, to improve BRFS, adequate inclusion of the SVB appears 
mandatory, especially in cases of positive surgical margins at the base of the prostate. 
 
Condensed Abstract 
 
In postoperative prostate cancer patients with positive surgical margins at the base of 
the prostate, adequate inclusion of the seminal vesicle bed in the radiation fields 
decreased biochemical recurrence. 
 
Introduction 
 
According to global cancer statistics in 2012, prostate cancer had the second highest 
estimated incidence in men, after lung cancer, and the fifth highest the mortality rate in 
men. Estimated age-standard incidence and mortality rates of prostate cancer in Eastern 
Asia were 31.1 and 7.8 per 100,000 men, respectively [1].  
Radical prostatectomy (RP) is a curative therapy for localized prostate cancer. However, 
about 15–30% of patients treated with RP experience biochemical recurrence (BRec) 
within 5 years [2-3]. Approximately one-third of patients with BRec after RP will have 
distant metastases, and the median time to the development of distant metastases 
following BRec is 8 years [3]. Salvage radiation therapy (SRT) has been reported as an 
 effective treatment for BRec after RP [4-16]. Reports have varied regarding prognostic 
factors for biochemical control after SRT. For example, pre-SRT prostate-specific 
antigen (PSA) level, SRT dose, pathological findings of RP specimens such as Gleason 
score (GS), surgical margin status (SM), seminal vesicle involvement (pSV), perineural 
invasion (pn), extraprostatic extension ≥ 2 mm, PSA doubling time (PSADT), 
concurrent hormone therapy, and early institution of SRT [4-16] have all been reported 
in various combinations. In our institution, intensity-modulated radiation therapy 
(IMRT) has been employed in SRT for BRec after RP since 2009. Treatment planning 
for the IMRT has been performed in accordance with Radiation Therapy Oncology 
Group (RTOG) guidelines [17]. Prior to the implementation of IMRT, 
three-dimensional conformal radiation therapy (3D-CRT) had been performed in SRT. 
However, the radiation fields of the 3D-CRT did not include the seminal vesicle bed 
(SVB), as recommended in the RTOG guidelines (Fig. 1). Hence, the relationship 
between radiation therapy method and biochemical control was investigated in the 
current study. Hitherto, the significance of radiation fields in SRT has rarely been 
reported.  
 
Materials and Methods 
 
Data regarding patients with prostate cancer who had undergone RP, experienced BRec 
without evidence of clinical disease, and received SRT in National Cancer Center 
Hospital from October 2002 to June 2014 were retrieved from the radiation oncology 
 database. All patients were examined by whole body computed tomography (CT) and 
bone scintigraphy and no macroscopic lesions were detected prior to initiation of the 
salvage therapy. One hundred twenty patients who met these criteria were 
retrospectively analyzed. Patients were excluded from the study if they underwent 
follow-up for less than one year. 
Salvage therapy after RP was instituted for BRec with a PSA value greater than or equal 
to 0.2 ng/mL [18,19], or in cases of patients in whom the attending urologists performed 
salvage therapy because PSA kept increasing from the nadir PSA value after RP despite 
values less than 0.2 ng/mL. In 36 patients, salvage therapy was begun with hormonal 
therapy (HT) and SRT followed. Other patients were treated initially with SRT with or 
without concurrent HT.  
The associations of clinical, pathological, and therapeutic parameters with various 
survival types were evaluated. For patients referred from other hospitals, all operative 
specimens from the referring hospitals were re-examined and reviewed pathologically 
in our institution. 
Demographic and treatment characteristics of the 120 patients are shown in Table 1. 
The median follow-up period after SRT was 62.9 months (range: 13–150 months). 
Median patient age at the time of RP was 61 years, and median initial PSA was 14.00 
ng/mL. Regarding GS of operative specimens, 60% of the patients had GS 7, and GS of 
one patient was unknown. In 74 patients, GS included Gleason grade (GG) of 5. In 
almost half of the patients (55 patients, 45.8%), SMs were positive for cancer cells. The 
 SM was positive at the base of the prostate in 15 patients, among whom 10 patients 
were treated with 3D-CRT. Tumors were classified as T2, T3a, T3b, and T4 in 41, 41, 
25, and 13 patients, respectively. T4 was diagnosed by bladder invasion in all patients. 
Median interval from RP to the beginning of salvage therapy was 739 days (range: 44–
3232 days). PSA nadir after RP and PSA at the initiation of salvage therapy were 0.024 
ng/mL and 0.423 ng/mL, respectively. Median PSADT before salvage therapy was 
170.7 days (range: 27.3–824.5 days). In 39 patients, salvage therapy after RP included 
HT with luteinizing hormone-releasing hormone (LHRH) and/or antiandrogen in 
addition to SRT. No patients underwent HT after SRT. Median duration of the HT was 
5 months (range: 1–58 months). Eighty-one of the 120 patients did not receive HT and 
were treated with SRT only.   
IMRT was performed in 33 patients (27.5%), whereas 3D-CRT with seven fields was 
employed in 87 patients (72.5%). Both IMRT and 3D-CRT were delivered with 15 MV 
X-rays from linear accelerators (Varian, Palo Alto, CA, USA). Prescription dose was 
the dose at the isocenter in 3D-CRT, while mean dose of the planning target volume 
corresponded to the prescription dose in IMRT. The prescribed doses were 64.8 Gy with 
a fractional dose of 1.8 Gy in 116 patients (96.7%) and 60 Gy in 2 Gy fractions in four 
patients (3.3%). In 10 patients with pathologically positive lymph node involvement, 
bilateral pelvic lymph node stations up to the upper margin of L5 were also irradiated. 
In six patients out of the 10, a dose of 45 Gy in 25 fractions to the pelvis was followed 
by 19.8 Gy in 11 fractions to the prostatic bed. In the remaining four patients, the 
 simultaneous integrated boost IMRT (SIB-IMRT) technique was used, consisting of 
prostatic bed irradiation of 64.8 Gy and bilateral pelvic lymph node irradiation of 52.2 
Gy, both in 36 fractions.  
RTOG guidelines proposed that the superior edge of the clinical target volume (CTV) 
should be level with the cut end of the vas deferens or 3-4 cm above the top of the 
symphysis, or the CTV should include seminal vesicle remnants in cases of pathological 
evidence of seminal vesicle involvement. [17] In the current patient series, the CTV of 
the IMRT was contoured in accordance with the RTOG guidelines; however, the SVB 
was included in the CTV in all patients, regardless of pathological tumor invasion of the 
seminal vesicles. On the other hand, the CTV of the 3D-CRT included only the prostatic 
bed, and the SVB was not included in the radiation fields (Fig. 1) [20]. 
BRec after SRT was defined as two consecutive PSA values ≥  0.2 ng/mL with the 
second date considered as the time of BRec after SRT. Complications due to SRT were 
evaluated according to the Common Terminology Criteria for Adverse Events 
(CTCAE) ver.4.0. Late toxicity was defined as morbidities occurring more than three 
months after SRT.  
BRec-free survival (BRFS), overall survival (OS), cancer-specific survival (CSS), and 
clinical recurrence-free survival (CRFS) were calculated according to the Kaplan-Meier 
method with the last date of SRT assumed as day 0. The log-rank test was applied to 
identify statistical differences. In the calculation of BRFS, BRec (two consecutive PSA 
values ≥  0.2 ng/mL) and the initiation of HT were considered as an event, with death 
without BRec treated as censored. In calculating CSS and CRFS, deaths from causes 
 other than prostate cancer were treated as censored. Multivariate Cox proportional 
hazards regression models were used to identify independent factors influencing BRFS 
after SRT. Variables with p values less than 0.05 in the univariate analysis were 
selected for the multivariate analysis. P-values less than 0.05 were considered 
statistically significant. Statistical analysis was performed with IBM SPSS Statistics 
(v19.0.0; IBM Corp., Armonk, NY, USA). 
 
Results 
Acute adverse events of grade ≥  3 were not observed. Late genitourinary (GU) events 
of grade 3 hematuria were observed in two patients at 67 and 110 months, respectively, 
after SRT. Neither patient took any anticoagulant or antiplatelet agents. Both patients 
received transurethral electrocoagulation, and one patient underwent hyperbaric oxygen 
therapy as well. No late gastrointestinal (GI) events of grade > 3 were observed. 
 
Five-year probabilities of BRFS, OS, CSS, and CRFS were 39.2%, 97.0%, 98.3%, and 
91.9%, respectively (Fig. 2). After SRT, BRec was observed in 65 patients, and HT was 
initiated in two patients before the diagnosis of BRec was established. Five patients died 
during the follow-up period, among whom three died of prostate cancer and the 
remaining two died of other cancers (renal and pancreas cancers). Clinical recurrences 
were detected in nine patients. Seven patients experienced bone metastasis, and one also 
had liver metastasis. Pelvic lymph node and subcutaneous metastases were each 
observed in one patient.  
  
In univariate analysis, BRFS was favorable with statistically significant differences in 
patients with PSA < 0.5 ng/mL at the initiation of salvage therapy (p = 0.005, 5-year 
BRFS 48.8% with PSA < 0.5 ng/mL vs. 25.9% with PSA 0.5 ng/mL); PSA values < 0.5 
ng/mL at the initiation of SRT (p < 0.001, 5-year BRFS 47.8% with PSA < 0.5 ng/mL 
vs. 9.1% with PSA ≥  0.5 ng/mL); positive SMs (p = 0.001, 5-year BRFS 64.3% with 
positive SM vs. 23.5% with negative SM); GG not including 5 (p < 0.001, 5-year BRFS 
62.9% with GS not including GG 5 vs. 25.7% with GS including GG 5); GS ≥  7 (p = 
0.002, 5-year BRFS % 49.0% with GS < 7 vs. 25.3% with GS ≥ 8); and IMRT (p = 
0.045, 5-year BRFS 56.6% with IMRT vs. 36.5% with 3D-CRT) (Fig. 3).  
Pathological T-stage ≥  3 (p = 0.067, 5-year BRFS 47.4% with T < 3 vs. 37.3% with T 
≥  3) was an unfavorable factor with marginal significance.  
On the other hand, SV involvement, positive lymph nodes, extracapsular invasion, 
lymphatic invasion, perineural invasion, PSA nadir after RP, administration of HT in 
salvage therapy, and PSADT had no statistically significant influence on BRFS (Table 
2). 
As a prognostic factor after the completion of SRT, PSA nadir after SRT was revealed 
to influence BRFS with statistical significance, with PSA nadir < 0.05 showing 
favorable outcome (p < 0.001, 5-year BRFS 61.6% with PSA nadir after SRT < 0.05 vs. 
7.6% with PSA nadir after SRT ≥  0.05). 
Multivariate Cox proportional hazards analysis included all possible variables prior to 
SRT (excluding PSA nadir after SRT) with p < 0.05 in the univariate analysis. However, 
 only a factor with a lower p-value was selected in the strongly interrelated prognostic 
factors. PSA values at the initiation of SRT and salvage therapy are strongly correlated; 
therefore, PSA at the initiation of SRT was selected. Moreover, because GS and the 
presence of GG 5 are interrelated with a lower p-value in the presence of GG 5, the 
presence of GG 5 was included in the multivariate analysis. The multivariate analysis 
revealed that the presence of GG 5 and PSA values ≥  0.5 ng/mL at the initiation of SRT 
were unfavorable prognostic factors for BRFS with statistical significance and for 
3D-CRT with marginally statistical significance (Table 2).  
 
Among patients treated with 3D-CRT, 32 had positive SMs. Ten patients had positive 
SMs at the base of the prostate, and 22 had positive SMs at other sites. BRFS was 
significantly different between these two patient groups (p = 0.004) (Fig. 4). Five-year 
BRFS was 40.0% and 86.4% in the patients with positive SMs at the base and at the 
other sites, respectively. In the 33 patients treated with IMRT, no difference was 
observed in BRFS according to the site of positive SM, partially because of the low 
number of patients undergoing IMRT. 
 
Discussion 
In this study, among patients without evidence of clinical disease at the initiation of 
salvage therapy, GS not including GG 5 and PSA values < 0.5 ng/mL at the initiation of 
SRT were proven to be favorable prognostic factors for BRFS by SRT after RP with 
statistical significance, and usage of IMRT favorably influenced BRFS with marginal 
 significance. These results were largely the same as those described in previous reports. 
However, in the present report, the relationship between BRFS and radiation dose, 
which has been demonstrated in past reports, was not analyzed because almost all 
patients received the same dose of 64.8 Gy. Radiation dose has been reported as an 
important prognostic factor [10-17]. According to Bernard et al. [11], in a high dose 
group (radiation dose > 66.6 Gy), BRFS was higher than in the low (radiation dose < 
64.8 Gy) and moderate (radiation dose; 64.8–66.6 Gy) dose groups. In a recent study 
[16], SRT doses ≥  68 Gy were associated with a reduced risk of BRec. The 5-year rates 
of BRFS with SRT doses of less than 66 Gy, 66–67.99 Gy, 68–71.99 Gy, and ≥  72 Gy 
were 46%, 44%, 53%, and 61%, respectively. Moreover, a systematic review and 
meta-analysis by King et al. [21] demonstrated a dose–response relationship between 
SRT dose and BRFS. A well fit sigmoidal relationship of dose and biochemical control 
showed 50% PSA control at a dose of 65.8 Gy. The results of this high dose irradiation 
were better than the BRFS achieved in the present study, and dose increment seems 
mandatory to improve BRFS of SRT for BRec after PR. 
To our knowledge, this is the first report that investigates the prognostic significance of 
the site of positive SMs. When all patients with a positive SM were analyzed, it was of 
marginal significance for BRFS whether the positive SM was at the base or at other 
sites. However, in patients treated with 3D-CRT, those with a positive SM at the base of 
the prostate showed poorer BRFS with statistical significance. In the current series, SRT 
by 3D-CRT did not include the SVB, in contrast to IMRT, which included the SVB (Fig. 
 1). It seems probable that this inadequacy of irradiation fields at the SVB in the 
3D-CRT caused poorer BRFS, especially in the patients with a positive SM at the base, 
which lies in the cranial part of the prostate bed. These findings indicate that SVB 
should also be included in the CTV in patients with a positive SM at the base, even in 
cases in which pathological SV invasion is not obvious. The findings also emphasize 
the importance of the cranial margins in SRT for BRec after RP. 
In RTOG 9601 [22], in which SRT of 64.8 Gy, a dose similar to that of the current 
series, was delivered to the BRec after PR, 5-year BRFS without antiandrogen therapy 
reached almost 50%, although only patients with less advanced disease, with pT2 and 
pT3, were recruited in RTOG 9601 in contrast to the current series, and a different 
definition of BRec was used. Poor BRFS in the current series could be partially caused 
by the inadequate radiation fields in 3D-CRT. 
Even in comparison to the results of the Japanese series of SRT for BRec after RP 
reported by Mizowaki et al, the 5-year BRFS in the present series was unfavorable 
(39.2% in the current series vs. 50.1% in the study by Mizowaki, et al.) [9]. In 
Mizowaki’s series, 40.9% of the patients received radiation doses of more than 65 Gy. 
Poorer results in the current series seem to be caused by the lower SRT dose and the 
inadequate radiation fields.  
Compared to previous reports, a lower incidence of late adverse events was observed in 
the present study. The reasons for this lower incidence of late adverse events are 
unknown, but the routine employment of 15 MV x-ray beams could be contributing in 
the reduction of rectal and bladder doses [23]. Implementation of IMRT further reduced 
 doses to the organs at risk and the incidence of adverse events [24, 25]. 
There are several limitations in this study. Firstly, the follow-up period of patients 
receiving IMRT was shorter than that of patients receiving 3D-CRT. Further follow-up 
of the patients undergoing IMRT is mandatory to confirm the superiority of IMRT in 
BRFS. Secondly, there exist some inhomogeneity concerning HT and PSA values 
before delivery of the salvage therapy. In some patients, salvage therapy was performed 
before their PSA values were higher than 0.2. Additionally, the length of HT ranged 
from 1 month to 58 months. However, multivariate analysis took all of these factors into 
account, which could have partially compensated for the inhomogeneity. Lastly, this 
report is a retrospective study and could include some unknown biases. 
In conclusion, this retrospective study found that SRT can be performed safely and that 
the presence of GG 5 and PSA values ≥  0.5 ng/mL at the initiation of SRT were 
unfavorable prognostic factors for BRFS. The inadequacy of radiation fields in the SVB 
affected BRFS adversely, especially in patients with a positive SM at the base of the 
prostate. Irradiation sufficiently including the SVB and dose escalation seem to be very 
important to improve the BRFS of SRT. 
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Table 1. Demographic and treatment characteristics of the 120 patients 
    
            Chracteristics       n (%) 
   
Total number of patients 
 
120 (100) 
   
Median age at the RP [range] 
 
61 years [49-76] 
  
Median initial PSA [range] 
 
14.00 ng/ml [3.60-73.51] 
   
RP operative pathology 
  
 
Operative Gleason score 
        
 
 6 
      
5 (4.2) 
   
 
3+4 
      
21 (17.5) 
   
 
4+3 
      
51 (42.5) 
   
 
 8 
      
42 (35.0) 
   
 
Gleason grade with 5 
    
74 (61.7) 
   
 
Positive surgical margin 
    
55 (45.8) 
   
 
Perineural invasion 
    
95 (79.2) 
   
 
Lymphatic invasion 
    
14 (11.7) 
   
 
Extra capsular invasion 
    
55 (45.8) 
   
 
Positive lymph nodes 
    
10 (8.3) 
   
 
Seminal vesicle involovement 
   
30 (25.0) 
   
Pathological tumor stage 
         
 
T2 
      
41 (34.2) 
   
 
T3a 
      
41 (34.2) 
   
 
T3b 
      
25 (20.8) 
   
 
T4 
      
13 (10.8) 
   
Median PSA nadir after RP [range] 
 
0.024 ng/ml [0.001-3.112] 
   
Median interval from RP to salvage therapy [range] 
 
739 days [44-3232] 
   
            
Median age at the SRT+ [range] 
 
66 years [51-77] 
   
Median PSA at the initiation of salvage therapy [range] 
 
0.423 ng/ml [0.091-8.172] 
   
Median PSA doubling time before salvage therapy [range] 
 
170.7 days [27.3-824.5] 
   
Salvage therapy with HT 
     
39 (32.5) 
   
  
 
 
  
Fig. 1. Comparison of the dose distributions of the three-dimensional conformal 
radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in this 
study. Seminal vesicle bed (SVB) was not irradiated in the 3D-CRT.  
  
Fig. 2. Biochemical recurrence-free survival (BRFS), overall survival (OS), 
cancer-specific survival (CSS), clinical recurrence-free survival (CRFS) of all patients. 
The 5-year rates of BRFS, OS, CSS, and CRFS were 39.2%, 97.0%, 98.3%, and 91.9%, 
respectively. 
  
Fig. 3. Biochemical recurrence-free survivals (BRFS) according to the PSA values at 
the initiation of salvage radiation therapy (SRT) and presence of Gleason grade (GG) 5 
in Gleason score (GS). 
  
Fig. 4. Biochemical recurrence-free survivals (BRFS) by the sites of positive surgical 
margin (SM) in patients treated with three-dimensional conformal radiation therapy 
(3D-CRT). 
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